Hj. Siegel et al., HEMARTHROSIS AND SYNOVITIS ASSOCIATED WITH HEMOPHILIA - CLINICAL USE OF P-32 CHROMIC PHOSPHATE SYNOVIORTHESIS FOR TREATMENT, Radiology, 190(1), 1994, pp. 257-261
PURPOSE: To evaluate the clinical usefulness of phosphorus-32 chromic
phosphate synoviorthesis in patients with hemophilia, recurrent hemart
hrosis, and synovitis. MATERIALS AND METHODS: Forty-four P-32 colloid
synoviorthesis procedures were performed in 38 patients with these abn
ormalities. P-32 colloid was injected intramuscularly in a dose of 1.0
mCi (37.0 MBq) in adult knees and 0.5 mCi (18.5 MBq) in adult elbows.
A thin-window Geiger-M uller counter was used to survey treated joint
s, lymph nodes, and liver in order to detect leakage from the joint. F
ollow-up extended to a maximum of 4 years after treatment. RESULTS: No
evidence of clinically significant leakage was seen. Twenty-two of 28
treatments (78%) with longer than 6 months follow-up were associated
with improvement in range of motion and frequency of hemorrhage. Of 15
treatments with longer than 2 years follow-up, 10 (67%) were associat
ed with improvement in range of motion; 12 (80%), with improvement in
frequency of hemorrhage; and 12 (80%), with improvement in quality-of-
life activities. CONCLUSION: P-32 colloid synoviorthesis is a clinical
ly useful outpatient procedure in patients with hemophilia, recurrent
hemarthrosis, and synovitis in whom hemostatic therapy has failed.